There are several novel medications in both early- and later-stage clinical development which hold out hope for new treatment options as well as many in earlier stages of the pipeline. If only one of these proved effective (for example Gly-T I inhibitors currently in Phase III trials), we could expect new options within a couple of years. The early stage medications, coming mainly from pharmaceutical companies, are at least 5 years away. A new pan-NIH-initiative to accelerate drug discovery via academic labs could yield fruit, with a fair amount of luck, within the 5-year timeline.
Bryan L. Roth, M.D., Ph.D.
Scientific Council Member
Michael Hooker Distinguished Professor
Director, NIMH Psychoactive Drug Screening Program
University of North Carolina Chapel Hill Medical School